CD47-SIRPα signaling pathway is an attractive target for novel therapies in hematological malignancies, indeed blockade of this axis can increase cancer cell clearance by macrophages and augment antigen cross-presentation for T-cell priming, thus enhancing both innate and adaptive anti-cancer immune response. The gene discussed is SIRPA; the disease is hematologic disorder.